TB-500 Research Overview (also known as Thymosin Beta-4 Fragment, TB500)
A synthetic fragment of Thymosin Beta-4, a naturally occurring peptide found in virtually every cell in the body. Its primary mechanism involves modulation of actin, enabling effective migration of repair cells to injury sites. Potently pro-angiogenic through VEGF upregulation. Studied for wound healing, musculoskeletal repair, cardiac tissue recovery, and anti-inflammatory effects.
For state-by-state regulatory and compounding context relevant to research peptides, consult the Peptide Laws by State hub.
For the regulatory discussion specific to TB-500 and other compounds considered by the FDA advisory panel, read FDA Advisory Panel Votes to Recommend BPC-157, TB-500, KPV, and MOTS-c for Compounding.
What Is TB-500?
TB-500 is a synthetic version of the 43-amino-acid peptide Thymosin Beta-4 (Tβ4) — specifically the active fragment comprising amino acids 17–23 of Tβ4. Thymosin Beta-4 is one of the most abundant intracellular peptides in mammalian cells and a key regulator of actin — the cytoskeletal protein essential for cell motility, wound healing, and tissue repair.
Mechanism: Actin Sequestration and Cell Mobility
TB-500's primary molecular function is sequestration of G-actin (globular actin monomers), preventing their polymerization into F-actin filaments and maintaining a pool of mobile actin available for directed cell migration. This action promotes the migration of keratinocytes, endothelial cells, and progenitor cells into wound sites — a rate-limiting step in tissue repair — dramatically accelerating wound closure, tendon healing, and muscle repair.
Angiogenesis, Cardioprotection, and Anti-inflammation
Beyond wound healing, TB-500 stimulates angiogenesis through upregulation of VEGF and VEGFR2. Primate studies showed TB-500 treatment after myocardial infarction resulted in new cardiomyocyte generation and improved cardiac function — positioning it in cardiac regenerative medicine research. TB-500 also downregulates NF-κB signaling, reducing pro-inflammatory cytokine production in a mechanism similar to BPC-157.
Quick Reference
| Literature-Reported Dose Range | 2-3mg |
| Literature-Reported Frequency | 2-3x weekly |
| Literature-Reported Cycle Length | 6-12 weeks |
| Literature-Reported Washout | 4-6 weeks |
| Storage | Fridge, 28 days |
| Sites Reported in Studies | Belly, thigh, shoulder |
| Timing | Flexible timing |
Research Indications
Tissue Repair
Muscle Regeneration
Accelerated healing of muscle fibers, reduced recovery time from muscle injuries, and enhanced muscle tissue repair through improved cell migration and differentiation.
Tendon & Ligament Healing
Promotes connective tissue repair, reduces scar formation, and improves biomechanical properties of healing tendons and ligaments.
Wound Healing
Enhanced dermal wound closure, improved angiogenesis, and reduced inflammation in both acute and chronic wound healing scenarios.
Athletic Recovery
Exercise Recovery
Faster recovery from intense training, reduced exercise-induced muscle damage, and improved adaptation to training stress.
Injury Prevention
Strengthened connective tissues, improved tissue resilience, and reduced risk of overuse injuries through enhanced tissue quality.
Performance Enhancement
Improved muscle fiber quality, enhanced endurance capacity, and better overall tissue function supporting athletic performance.
Neurological
Neuroprotection
Protective effects against neuronal damage, reduced neuroinflammation, and support for nervous system recovery following injury.
Spinal Cord Support
Enhanced recovery in spinal cord injury models through neuroprotective and anti-inflammatory mechanisms.
Brain Health
Potential benefits for brain injury recovery, improved neuroplasticity, and protection against neurodegenerative processes.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| General tissue repair | 2-3mg | 2x weekly | SubQ or IM |
| Serious injury recovery | 4-5mg | 3x weekly | SubQ near injury site |
| Athletic enhancement | 2-3mg | 2x weekly | SubQ |
| Chronic conditions | 3-4mg | 2-3x weekly | SubQ or IM |
Timing
Recommended administration window: flexible timing. Typical onset: 2-4 weeks.
Peptide Interactions
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
Complementary healing mechanisms with enhanced tissue repair when used together
TB-500 may enhance tissue sensitivity to growth hormone effects
TB-500 tissue repair combined with GH-releasing effects for comprehensive recovery
Enhanced muscle and tissue regeneration through complementary growth pathways
No known negative interactions, potential for enhanced recovery
No interaction expected - TB-500 promotes tissue repair via actin regulation, Melanotan II acts on melanocortin receptors. Completely different receptor families with no pathway overlap.
Reported Research Timeline
01Week 1–2 (reported in cited studies): reduced inflammation and improved tissue sensation
02Week 2–4 (reported in cited studies): accelerated healing rate and improved tissue quality
03Week 4–8 (reported in cited studies): maximum tissue repair and regenerative benefits
04Week 6–12 (reported in cited studies): continued improvement in tissue strength
05Most effective for: Muscle, tendon, ligament injuries
Side effects (reported in cited studies): generally minimal
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Use sterile injection technique to prevent infection
Mild injection site reactions are normal and temporary
Consult healthcare provider if on immunosuppressive medications
Not recommended during active cancer treatment
Avoid during pregnancy or breastfeeding
WADA prohibited - not for competitive athletes
Seek Medical Attention If:
Persistent injection site infections
Unusual swelling or prolonged redness
Severe allergic reactions
Unexpected systemic symptoms
Any concerning changes in health
Always consult your healthcare provider
Quality Indicators
Verified Marker
White Lyophilized Powder
TB-500 should appear as a white to off-white, fine powder that is evenly distributed in the vial. Proper lyophilization creates a light, fluffy texture.
Verified Marker
Clear Solution After Reconstitution
When properly reconstituted with BAC water, TB-500 should form a completely clear, colorless solution with no visible particles or cloudiness.
Verified Marker
Proper Vacuum Seal
Vial should have intact vacuum seal with no cracks or damage. The rubber stopper should be secure and show no signs of contamination.
Acceptable Range
Slight Powder Clumping
Minor clumping during shipping is acceptable if it dissolves completely with gentle swirling. Avoid shaking vigorously.
Quality Concern
Colored or Crystalline Powder
Any discoloration (yellow, brown) or crystalline appearance may indicate degradation or contamination. Should appear as fine white powder only.
Quality Concern
Persistent Cloudiness
If solution remains cloudy, has floating particles, or shows precipitation after reconstitution, the peptide may be degraded or contaminated.
Research Citations
- Cardiac Tissue Regeneration (2016)
Human Clinical Trial | IV administration | Improved cardiac function - Muscle Fiber Regeneration (2015)
Mouse Model | 6 months | Enhanced skeletal muscle repair - Corneal Healing Research (2014)
Human Phase 2 | Eye drops | Improved dry eye symptoms - Dermal Wound Healing Study (2012)
Human Phase 2 | Topical application | Accelerated healing rate - Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield CK, Bolia IK, Feingold CL, 2026, Am J Sports Med - Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry
Thomas A, Görgens C, Guddat S, 2016, J Sep Sci
Research Focus
Wound healing, Tissue repair, Angiogenesis, Anti-inflammatory, Muscle injury, Actin regulation
Verified Vendors Carrying TB-500
Frequently Asked Questions
What should researchers watch for with TB-500?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with TB-500?
Week 1–2 (reported in cited studies): reduced inflammation and improved tissue sensation
How is TB-500 typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →